ArQule, Phase 1/2 Clinical Trial Program of ARQ 197 in Non-Small Cell Lung Cancer

March 13, 2008--ArQule, Inc. (NASDAQ: ARQL) announced the commencement of patient dosing in a Phase 1/2 clinical trial program of ARQ 197 administered in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase. Erlotinib, marketed as Tarceva(R), is an inhibitor of the EGFR (epidermal growth factor receptor) tyrosine kinase... ArQule's Press Release -